

SJR60 INTRODUCED



1 SJR60
2 V7SH4LL-1
3 By Senator Givhan
4 RFD: RULES
5 First Read: 25-Feb-26



1
2
3
4 SJR___ ENCOURAGING THE ALABAMA MEDICAID AGENCY TO EVALUATE
5 THE OVERALL COSTS OF GLP-1 MEDICATIONS AND REPORT ITS
6 FINDINGS.

7
8 WHEREAS, obesity is caused by a complex mix of
9 environmental and biological factors, and it puts
10 individuals at risk for other diseases, such as heart
11 disease and diabetes; and

12 WHEREAS, in 2019, the Centers for Disease Control
13 reported that obesity accounted for nearly \$173 billion in
14 medical expenditures annually in the United States;
15 GlobalData estimates that obesity has negatively impacted
16 the State of Alabama's GDP by \$7.2 billion and annually
17 impacts the state budget by over \$750 million; 2024
18 Behavioral Risk Factor Surveillance System data estimates
19 the prevalence of obesity in Alabama is estimated at 38.9
20 percent for adults and 15.6 percent for children enrolled in
21 the Women, Infants, and Children program in Alabama; and

22 WHEREAS, the Centers for Medicare and Medicaid
23 Services recently launched two new drug pricing models that
24 could positively impact Medicaid programs; the true impact
25 will be known when the participating manufacturers and
26 medications are announced by Spring 2026, approximately; and

27 WHEREAS, the Alabama Medicaid Agency estimates
28 approximately 110,000 adult and child members may qualify



SJR60 INTRODUCED

for GLP-1 medications for weight management based on current FDA labeling; it is important to determine whether GLP-1 medications could benefit Alabamians; now therefore,

BE IT RESOLVED BY THE LEGISLATURE OF ALABAMA, BOTH HOUSES THEREOF CONCURRING, That the Alabama Medicaid Agency is encouraged to:

(1) Determine actual savings that might exist in all facets of the program should coverage of GLP-1 medications be appropriate;

(2) Evaluate the overall costs of coverage of GLP-1 weight management medications in the context of potential savings from new drug pricing models;

(3) Continue to have conversations with providers and stakeholders in an effort to achieve optimal improved health outcomes and cost savings for the State of Alabama should coverage be appropriate; and

(4) Report its findings to the Legislature prior to the 2027 Legislative Session.